Stockscreener 앱 받기
11.75
1.47%
0.169
전일 마감가:
$11.58
열려 있는:
$11.43
하루 거래량:
44,319
Relative Volume:
0.28
시가총액:
$930.56M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.25%
1개월 성능:
+31.43%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.93
$11.75
1주일 범위
$10.85
$11.94
52주 변동 폭
$8.70
$12.50
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
명칭
Bridgebio Oncology Therapeutics Inc
전화
857 702 0377
주소
C/O CORMORANT ASSET MANAGEMENT, LP, BOSTON
BBOT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
11.75 | 917.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.44 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.14 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.44 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
773.99 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
345.21 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc 주식(BBOT)의 최신 뉴스
BridgeBio Oncology Therapeutics Inc (NASDAQ: BBOT) Is Up 8.01% – Is It Capable Of A Rally? - stocksregister.com
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform (BBOT:NASDAQ) - Seeking Alpha
Leerink Partners Initiates BridgeBio Oncology Therapeutics at Outperform - MarketScreener
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating - Investing.com India
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com UK
HC Wainwright Initiates BridgeBio Oncology Therapeutics at Buy With $27 Price Target - MarketScreener
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com India
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer By Investing.com - Investing.com Nigeria
Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target - MarketScreener
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - MSN
BridgeBio Oncology Therapeutics shares rise 4.57% after-hours after announcing participation in September investor conferences. - AInvest
BBOT to Participate in Upcoming September Investor Healthcare Conferences - The Manila Times
BBOT to Participate in Upcoming September Investor Healthcare Conferences - GlobeNewswire Inc.
BridgeBio's Strategy To Unleash The Full Potential Of RASDrugging The Undruggable - RTTNews
BridgeBio Oncology Therapeutics shares rise 11.34% premarket after Wedbush initiates coverage. - AInvest
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely - Yahoo Finance
We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth - simplywall.st
BridgeBio Oncology Therapeutics shares rise 1.17% intraday after Piper Sandler initiates coverage. - AInvest
Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target - MarketScreener
BridgeBio Oncology initiated with an Overweight at Piper Sandler - TipRanks
Bridgebio Oncology Therapeutics, Inc. shares rise 2.12% intraday after Helix Acquisition Corp. II retains more than 60% of trust account. - AInvest
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating - Investing.com
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics | Silicon Investor (SI) -- The First Internet Community - FinancialContent
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer - Business Wire
Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
BridgeBio enters the pan-KRAS game | ApexOncoClinical Trials news and analysis - Oncology Pipeline
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
BridgeBio Oncology Therapeutics Coverage - MedCity News
BridgeBio spinout to go public in SPAC deal (HLXB:NASDAQ) - Seeking Alpha
Seven biotech spinouts to watch out for in 2025 - Labiotech.eu
BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC - OncLive
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS - Business Wire
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRASG12C Mutant Tumors - BioSpace
Unnatural Products Announces BridgeBio Exercises Option to - GlobeNewswire
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - Business Wire
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Business Wire
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer - Business Wire
BridgeBio launches another new company, GondolaBio - The Pharma Letter
BridgeBio forms another offshoot with $300M in commitments - Endpoints News
How Computer-Aided Drug Discovery Is Leading to Revolutionary Cancer Treatment - Tech Briefs
Bridgebio Oncology Therapeutics Inc (BBOT) 재무 분석
Bridgebio Oncology Therapeutics Inc (BBOT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.01%
자본화:
|
볼륨(24시간):